Blueprint Medicine Gains US Approval For First Drug, Precision Medicine Ayvakit
Targets Mutation In GIST tumors
Executive SummaryThe FDA has granted full approval to the drug based on Phase I efficacy data and safety studies, reflecting lack of existing treatment options
You may also be interested in...
Accelerated approval in epithelioid sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.
Highlights of year-end application submissions including candidates from AstraZeneca, BioMarin, Lilly, MorphoSys, and Seattle Genetics.
The Coalition for Epidemic Preparedness Innovations adds new deal with mRNA specialist Moderna for rapid development of coronavirus vaccine.